2 recruiting, 1 active not recruiting, 1 terminated. 2 Phase 1, 2 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Active not recruiting 1, Recruiting 1 |
| Phase 3 | 2 | Recruiting 1, Terminated 1 |
| Phase 2 | 1 | Active not recruiting 1 |
Follow Metastatic HER2-Positive Breast Carcinoma: new trials by email Literature Review of Metastatic HER2-Positive Breast Carcinoma trials Research Report on Metastatic HER2-Positive Breast Carcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Adding Surgery and Radiation to the Usual Treatment for HER2-Positive Breast Cancer That Had Already Spread at Diagnosis Biopsy Procedure, Biospecimen Collection, Breast Conservation Treatment - Anatomic Stage IV Breast Cancer AJCC v8, Metastatic HER2-Positive Breast Carcinoma | Phase 3 | Recruiting | SWOG Cancer Research Network | 562 | 2027-03-09 | 2026-10-13 |
| Testing the Safety of the Combination of Anti-Cancer Drugs CX-5461 (Pidnarulex) and Trastuzumab Deruxtecan (T-DXd) for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Solid Tumors and Breast Cancer Biopsy Procedure, Biospecimen Collection, Echocardiography Test - Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8 | Phase 1 | Recruiting | National Cancer Institute (NCI) | 36 | 2026-10-06 | 2026-10-16 |
| Ribociclib, Tucatinib, and Trastuzumab for the Treatment of HER2 Positive Breast Cancer Carboplatin, Docetaxel, Fulvestrant - Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8 | Phase 1 / Phase 2 | Active not recruiting | Jonsson Comprehensive Cancer Center | 18 | 2022-04-07 | 2026-05-11 |
| Testing the Drug Atezolizumab or Placebo With Usual Therapy in First-Line HER2-Positive Metastatic Breast Cancer Atezolizumab, Biopsy, Bone Scan - Metastatic Breast Adenocarcinoma, Metastatic HER2-Positive Breast Carcinoma | Phase 3 | Terminated | National Cancer Institute (NCI) | 190 | 2019-04-05 | 2026-05-29 |
Breast Neoplasms (2) · Neoplasm Metastasis (1) · Triple Negative Breast Neoplasms (1)
Breast Diseases (2) · Neoplasms (2) · Neoplasms by Site (2) · Skin Diseases (2) · Skin and Connective Tissue Diseases (2) · Neoplastic Processes (1) · Pathologic Processes (1) · Pathological Conditions, Signs and Symptoms (1)
2C4 antibody (3) · Biopsy (3) · Ogivri (3) · Ontruzant (3) · PF-05280014 (3) · Trastuzumab (3) · pertuzumab (3) · trastuzumab biosimilar HLX02 (3) · CT-P6 (2) · Docetaxel (2) · Magnetic Resonance Spectroscopy (2) · Specimen Handling (2) · trastuzumab deruxtecan (2) · Ado-Trastuzumab Emtansine (1) · CX 5461 (1)
National Cancer Institute (NCI) (2) · Jonsson Comprehensive Cancer Center (1) · SWOG Cancer Research Network (1)
United States (4) · Canada (1)
Charles E Geyer (1) · Filipa Lynce (1) · Mariya Rozenblit (1) · Nicholas P McAndrew (1)
U10CA180868 (1), U10CA180888 (1), UM1CA186709 (1)